WEBULL
WebtradeDownload

Jenscare Scientific (SEHK:9877) Stock Rallies Into A Steep Valuation Puzzle

Simply Wall St · 1d ago

Jenscare Scientific stock closed at HK$7.42, with the recent 7 day gain of about 5% suggesting that traders welcomed the headline improvement. The headline itself is simple. Losses are shrinking, while the price tag on those losses remains steep.

H1 2026 basic earnings per share narrowed to a loss of ¥0.11 and net loss came in at ¥48.69 million. Yet the stock still trades on a P/S ratio of 18.8x, compared with single digit multiples across Hong Kong medical equipment peers. The short term bounce sits alongside a longer term question about how much potential recovery is already reflected in the price.

Interested in Jenscare Scientific's shrinking losses but wary of paying a premium multiple for a company still in the red? You can compare it with stocks that pair stronger fundamentals and more modest valuations in our list of solid balance sheet and fundamentals stocks (437 results).

H1 2026 Earnings Summary

  • Revenue (H1 2026 vs. H1 2025): ¥64.131 million vs. ¥13.426 million (higher revenue in the latest half year)
  • Net Loss (H1 2026 vs. H1 2025): ¥48.69 million loss vs. ¥169.565 million loss (losses narrowed in the latest half year)
  • Basic EPS (H1 2026 vs. H1 2025): ¥0.11 loss per share vs. ¥0.414651 loss per share (smaller loss per share in the latest half year)
  • Trailing 12 Month Net Loss (to H1 2026 vs. to H1 2025): ¥150.354 million loss vs. ¥244.814 million loss (losses reduced on a trailing 12 month basis)

Prefer clear visuals instead of another dense block of numbers on Jenscare Scientific? Get a full picture of the stock's valuation setup in an easy-to-read dashboard through the company report for Jenscare Scientific..

SEHK:9877 Trailing 12-Month Earnings & Revenue History as at Sep 2026
SEHK:9877 Trailing 12-Month Earnings & Revenue History as at Sep 2026

Jenscare Scientific results that support the optimists

The latest half year gives Jenscare Scientific bulls some grounded talking points. Revenue for H1 2026 is ¥64.131 million compared with ¥13.426 million a year earlier, which points to stronger commercial traction around the product suite. At the same time, the net loss for the half narrowed to ¥48.69 million and basic EPS loss shrank to ¥0.11. Taken together with a smaller trailing 12 month loss, that tilt in the income statement leans toward a story of improving operating scale rather than stalled execution.

Where the Jenscare bear case still bites

For cautious investors, Jenscare Scientific’s latest results do not remove the key risk that the business is still losing money. A net loss of ¥48.69 million in H1 2026 and a trailing 12 month loss of ¥150.354 million keep funding and execution risk firmly on the table for an R&D heavy medtech company. The 90 day share return of a decline of about 6% also suggests that the market has not fully bought into a smooth path to profitability, even with the recent 7 day bounce.

Jenscare Scientific has reduced losses, but the business still reports a ¥150.354 million trailing 12 month loss, so funding and runway are key questions. Check whether the balance sheet and cash position really support this trajectory in the financial health analysis of Jenscare Scientific stock.

Take Control Of Your Next Move

If Jenscare Scientific's shrinking losses and premium P/S ratio have caught your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for a more comfortable entry point. Once you commit capital, use the Portfolio Command Center to cut through market noise and focus on essential updates that matter for your holdings. For longer term decisions, lean on the collective insight inside the Community to see how other investors are thinking about opportunities and risks. By surfacing potential catalysts and red flags early, you give yourself a better chance of staying ahead of the market.

Seeking Alternatives Beyond Jenscare Scientific

Fresh stock ideas can move fast. Some are building quiet momentum while others are close to a breakout and may be flying under the radar for now. Do not delay, get in early.

  • Spot companies with strong income potential and keep your cash working harder by scanning the curated list in the 417 dividend fortresses.
  • Hunt for fast movers in emerging AI themes and track where capital might be building next by reviewing the 55 AI infrastructure stocks while it still feels under the radar.
  • Target businesses linked to long term metals demand and see which producers are gaining momentum early through the 9 top copper producer stocks before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.